Biotronik SE & Co. KG announced the U.S. launch of the Ilesto DX implantable cardioverter defibrillator on Oct. 1. The ICD offers the atrial signal accuracy and reliable sensing and processing of its established DX technology in a thinner and smaller device. The firm’s DX technology, first sold in devices launched in February 2013, provides full atrial diagnostic information with one specialized defibrillator lead rather than two leads, according to the company. Ilesto DX is 15 percent smaller and has 29 percent fewer components than previous Biontronik ICDs with, the company claims, no compromise in longevity or clinical features.
Biotronik announced FDA approval of the Ilesto line of implantable cardioverter-defibrillator/cardiac resynchronization therapy defibrillators in May. The company says they combine the benefits of both single- and dual-chamber ICDs to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?